AquaBounty: FDA could approve biotech salmon this year

04/24/2013 | Hartford Courant (Conn.), The

AquaBounty Technologies expects its biotech salmon, which grows twice as fast as traditional salmon, to be approved by the FDA before the year ends. "There have been no new legal issues, no new regulatory issues, no new environmental issues raised," CEO Ronald Stotish said at the BIO International Convention. The public comment period ends on Friday, and the FDA's decision could come 150 to 180 days later, Stotish said.

View Full Article in:

Hartford Courant (Conn.), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN